Cyteir Therapeutics Inc CYTT
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.cyteir.com
Comparables
Valuation
|
Metric
|
CYTT
|
PRLD
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.87 | 0.64 | 8.23 |
Price/Sales | — | — | 350.69 |
Price/Cash Flow | — | — | — |
Price/Earnings
CYTT
PRLD
IGMS
Financial Strength
|
Metric
|
CYTT
|
PRLD
|
IGMS
|
|---|---|---|---|
Quick Ratio | 21.66 | 7.71 | 6.81 |
Current Ratio | 21.89 | 7.83 | 7.06 |
Interest Coverage | — | — | — |
Quick Ratio
CYTT
PRLD
IGMS
Profitability
|
Metric
|
CYTT
|
PRLD
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −20.38% | −40.98% | −45.61% |
Return on Equity (Normalized) | −21.31% | −46.70% | −95.44% |
Return on Invested Capital (Normalized) | −21.25% | −44.57% | −84.94% |
Return on Assets
CYTT
PRLD
IGMS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rymhkfvn | Cxvc | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bzzvxhs | Qfsyy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Btpxptbtq | Byggkxb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tsvhkswjy | Zbhvd | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Msjjwhgl | Cln | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rzxzbpzp | Bvqsg | $28.1 Bil | |||
| Moderna Inc
MRNA
| Gyfhwsgrj | Kptxd | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Tjdrmyh | Dfc | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bfsfvpgb | Ggqwhd | $13.4 Bil | |||
| Incyte Corp
INCY
| Ckzwgmsq | Dgnwtcm | $12.7 Bil |
United States